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ABSTRACT
Local anesthetics (LA) belong to a class of
pharmacological compounds that attenuate or eliminate
pain by binding to the sodium channel of excitable
membranes, blocking the influx of sodium ions and the
propagation of the nerve impulse. S (-) bupivacaine (S(-)
bvc) is a local anesthetic of amino-amide type, widely
used in surgery and obstetrics for sustained peripheral
and central nerve blockade. This article focuses on the
characterization of an inclusion complex of S(-) bvc in
2-hydroxypropyl- -cyclodextrin (HP- -CD). Differential
scanning calorimetry, scanning electron microscopy and
X-Ray diffraction analysis showed structural changes in
the complex. In preliminary toxicity studies, the cell
viability tests revealed that the inclusion complex
decreased the toxic effect (p<0.001) produced by S(-) bvc.
These results suggest that the S(-) bvc:HP- -CD inclusion
complex represents a promising agent for the treatment
of regional pain.
Keywords:  S(-) bupivacaine; cyclodextrin; inclusion
complex.
INTRODUCTION
Local anesthetics (LA) belong to one of the classes
of pharmacological compounds used to attenuate or eliminate
pain. These drugs, which inhibit reversibly the excitation-
transmission process in axons, have a relatively short-term
action and a significant toxicity to the central nervous and
cardiovascular systems (Covino & Vassalo, 1976; Strichartz
& Ritchie, 1987; Jong, 1994). Nowadays, there is a strong
clinical need for long-acting LA, as well as for drug molecules
with decreased systemic uptake that could lead to less toxic
side effects.
Bupivacaine is an amino-amide type local anesthetic
widely used in surgery and obstetrics for sustained peripheral
and central nerve blockade. The molecule has a single chiral
centre and the drug is marketed as the racemic mixture of
R(+) and S(-) bupivacaine (rac-bupivacaine). Both
enantiomers are active but the S(-) form has a longer duration
of neural blockade, as well as a lower toxicity towards the
central nervous and cardiovascular systems  (Mather et al.,
1995; Huang et al., 1998; Gristwood, 2002).(Figure 1)
Figure1. Chemical structure of  S(-) bupivcaine.
This has led to the introduction of S(-) bupivacaine
into clinical practice, under the name levobupivacaine (Foster
& Markham, 2000). Its safety and efficacy has been compared
with that of rac-bupivacaine in surgical anesthesia and pain
management (Foster & Markham, 2000).
Although commercially available local anesthetic
formulations are used in a variety of doses and routes of
administration, the relatively short duration of action - due
to the transfer and redistribution of the agent from the site of
injection - restricts their clinical use (Grant & Bansinath,
2001; Rose et al., 2005).
Thus, controlled-release systems would be highly
desirable for the clinical use of local anesthetics, offering
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the possibility of prolonging their duration of action and/or
reducing their toxicity (Hirayama & Uekama,1999; Araújo
et al., 2005; Rose et al., 2005).
Cyclodextrins are cyclic oligosaccharides capable
of forming complexes with lipophilic drugs, thus modifying
their physicochemical and biopharmaceutical properties
(Bibby et al., 2000). The  -,  -,  -cyclodextrins are widely-
used natural cyclodextrins that consist of six, seven and eight
D-glucopyranose residues, respectively, linked by  -1,4
glycosidic bonds into a macrocycle with a central cavity.
Owing to their ability to alter the physical, chemical, and
biological properties of guest molecules occupying the cavity,
cyclodextrins are potential candidates for drug delivery
devices (Ren et al., 2002).
The principal advantages of natural cyclodextrins
as drug carriers are: a well-defined chemical structure with
many potential sites for chemical modification or
conjugation; the availability of cyclodextrins of varying
cavity sizes, low toxicity and low pharmacological activity;
some degree of water solubility, and protection of the
included/conjugated drugs from biodegradation
(Thompson, 1997).
In fact, examples exist in the literature that
demonstrate the advantages of controlled release of LA in
cyclodextrin, such as prolonged action and reduced toxicity
(Araujo et al., 2005; 2006; Pinto et al., 2005). The purpose
of the present study was to prepare, characterize and assess
the cytotoxic activity of a S(-) bvc inclusion complex with
HP- -CD, in comparison with a plain solution of S(-) bvc.
This particular system has clinical relevance enabling the
use of S(-) bvc as an alternative means of pain treatment.
MATERIAL AND METHODS
Reagents and chemicals
S(-) Bupivacaine was a gift from Cristália Ind. Farm.
LTDA (Itapira, Brazil); HP- -CD was purchased from
Roquette and was characterized as having a degree of
substitution of 4.2, based on  Fourier-transformed infrared
spectrophotometric (FT-IR) analysis (Michaud & Icart,
2001). Sodium dihydrogen phosphate and disodium
hydrogen phosphate (anhydrous) were from Sigma Chem.
Co. and Deionized water (resistivity 18m .cm) from a Waters
ultra pure water system.
Preparation of solid inclusion complex
The inclusion complex was prepared by shaking
appropriate weights of the S(-) bvc and HP-  -CD (1:1 molar
ratio) in deionized water, at room temperature (25   1 °C)
for 24 h. After reaching equilibrium, the solution was freeze-
dried in a Freezone® 4.5L freeze-dry system (Labconco)
and stored at -20 °C for further use. A physical mixture
(uncomplexed drug) was prepared by mixing S(-) bvc and
HP- -CD powders.
Differential Scanning Calorimetry
The various samples (2 mg) were placed in
aluminum pans in a DSC2920 TA Instruments calorimeter
(University of São Paulo) and heated from 25-300 °C at 10oC/
min, in nitrogen flowing at 50mL/min. An empty pan served
as reference and pure Indium was used to calibrate the
temperature. Measurements were performed on the S(-)
bvc:HP- -CD inclusion complex (molar ratio 1:1) and the
equivalent physical mixture; S(-) bvc and HP- -CD
thermograms were also run.
Scanning Electron Microscopy
The S(-) bvc:HP- -CD inclusion complex (1:1
molar ratio) was morphologically analyzed by Scanning
Electron Microscopy (SEM), with a JEOL J-210 Scanning
Microscope. Samples of S (-) bvc, HP- -CD and the S(-)
bvc:HP- -CD physical mixture (1:1) were also prepared at
the same concentration as the inclusion complex. The samples
were mounted on aluminum stubs, using double-sided sticky
tabs, and vacuum coated with gold for 180 s, to render them
electrically conductive.
X-Ray analysis
Powder diffractograms of HP- -CD, S(-) bvc,
physical mixture and the inclusion complex were collected
on a Rigaku wide-Angle goniometer with a Co-K  radiation
source (Philips PW 1743) and voltage and current set to 40
kV and 20 mA, respectively, operated at a scan rate of 1°/
min, between 2  = 5° and 60° in a -2  configuration with
a pyrolytic graphite crystal analyzer.
Cell culture and cytotoxic assays
Balb/c mouse fibroblasts (3T3 cells) were
cultured in DMEM (Dulbecco´s Modified Eagle Medium)
supplemented with 10% fetal bovine serum, 100UI/mL
penicillin and 100 g/mL streptomycin sulfate (pH 7.2-7.4)
under a humidified atmosphere, at 37oC and 5% CO2.
Cells were seeded (2x104 cells/well) in 48-well tissue
culture plates and cultured for 48h. The cells were then
incubated for 2h with the test compound (S(-) bvc, HP- -
CD or complex) at three different concentration 0.2, 0.4
and 0.6 mM. Cell viability was assessed by tetrazolium
reduction (MTT test). 1mg/mL MTT was incubated for
1h with the treated 3T3 cells, at 37oC. The number of
viable cells was determined by measuring the amount of
MTT converted to insoluble formazan dye by
mitochondrial dehydrogenases. The formazan crystals
formed were dissolved in a 1 M HCl-isopropyl alcohol
mixture (1:24 v/v) and shaken for 20 min at room
temperature. Cytotoxic assay data were analyzed by one-
way analysis of variance (one-way ANOVA), with Tukey-
Kramer as a post hoc test. Statistical significance was
defined as p< 0.05.
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RESULTS
Differential Scanning Calorimetry (DSC)
Representative DSC thermograms measuring the
rate of heat absorption by S(-) bvc, HP- -CD, S(-) bvc:HP-
 
-CD inclusion complex (at 1:1 molar ratio) are shown in
Figure 2. The DSC thermogram of free S(-) bvc exhibited
an endothermic peak at 262.5 oC, corresponding to the
melting point of this compound (Loftsson & Brewster, 1996).
The thermogram for HP- -CD showed one broad
endothermic peak near 100oC, corresponding to the release
of water from HP- -CD (Kohata et al., 1993). The
thermogram of the S(-) bvc:HP- -CD physical mixture was
similar to that of S(-) bvc, with an endothermic peak at 262.5
(data not shown), whereas this peak was absent from the
thermogram for the S(-) bvc:HP- -CD complex.
Scanning Electron Microscopy (SEM)
Figure 3 shows that the shape and size of the
inclusion complex was completely different from those of
Figure 3. Scanning electron micrographs of (A) S(-) bvc, (B) lyophilized
HP- -CD, (C) physical mixture of S(-) bvc and HP- -CD(1:1, molar
ratio), (D) inclusion complex of S(-) bvc and HP- -CD (1:1, molar ratio).
2000 x magnification, bar = 10  m.
Figure 2. : Differential scanning calorimetry thermograms of HP- -CD,
S(-) bvc and c) S(-) bvc:HP- -CD 1:1 inclusion complex.
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free S(-) bvc or HP-  CD. The physical mixture of S(-) bvc
and HP- -CD powders (Figure 3C) revealed similarities with
the crystals of free molecules. At the 1:1 molar ratio of the
S(-) bvc:HP- -CD inclusion complex under study, a compact
and homogeneous powder-like structure was observed
(Figure 3D) which was smaller than the crystals of S(-) bvc
or HP- -CD alone.
X-Ray analysis
The diffractograms of S(-) bvc, HP-  -CD, physical
mixture and inclusion complex are shown in Figure 4. It can
be seen that HP- -CD and the complex gave patterns typical
of amorphous material, while samples containing the free
drug (Figure 4C and 4 D) showed crystallinity.
Cell culture and cytotoxic assays
Measurement of the effect of S(-) bvc, the complex
and HP- -CD on the 3T3 cell viability is a way to evaluate
the cytotoxicity of these chemical substances. The 3T3 cells
were treated at three different concentrations (0.2, 0.4 and
0.6 mM) of each compound. Figure 5 shows the effect of
concentration on the 3T3 cell viability (%), with significant
differences between the results for S(-) bvc and the S(-)
bvc:HP- -CD complex.
DISCUSSION
The use of DSC in combination with other
experimental techniques, such as X-ray, infrared, HPLC, UV-
Vis, scanning electron microscopy and NMR, is very useful
for the study of the properties of inclusion complexes (Naidu
et al., 2004). Simultaneous analysis of complexation
behavior by these different methods obviously has many
advantages, providing definitive experimental evidence for
the formation of the drug-cyclodextrin inclusion complex.
In the current study, further information about the complex
of S(-) bvc with HP- -CD has been obtained from DSC,
SEM, X-Ray data and cytotoxicity assays.
The thermogram for the inclusion complex shows
the absence of the characteristic endothermic peak of S(-)
bvc at 262.5 oC (Figure 2), indicating the formation of an
amorphous solid dispersion. The disappearance or shifting
of endo- or exothermic peaks of drugs is usually an indication
of changes in the physicochemical characteristics of the
system (Loukas et al., 1997). Here, it shows the absence of
uncomplexed S(-) bvc.
Scanning electron microscopy (SEM) can be used
to study the microscopic aspects of  raw materials
(cyclodextrin and drug) and the products obtained by different
methods of preparation, such as physical mixture, solution
complexation, coevaporation, etc. Although there is a clear
difference in the state of crystallization of the raw materials
and the products, in these micrographs, this alone is
inadequate to affirm inclusion complexation; nevertheless,
it helps to assess the existence of a single component in the
preparation obtained, such as the inclusion complex in Figure 3.
Powder X-ray diffractometry is a useful method for
the detection of cyclodextrin complexation in powder or
microcrystalline states. The diffraction pattern of the complex
should be clearly distinct from that of the superimposition
of each of the components if a true inclusion complex has
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Figure 4. The X-ray powder diffraction patterns of a) HP- -CD, b) S(-) bvc:HP- -CD
inclusion complex, c) S(-) bvc/HP- -CD 1:1 physical mixture  and d) S(-) bvc.
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been formed. Crystallinity was determined by comparing
some representative peak heights in the diffraction patterns
of the binary systems with those of a reference. The S(-) bvc
diffractogram clearly reveals a crystalline (Figure 4d) nature
while HP- -cyclodextrin is amorphous (Figure 4a). The
physical mixture of S(-) bvc and HP- -CD gave superposed
patterns of crystalline bupivacaine and the amorphous HP-
-CD (Figure 4c). On the other hand, the inclusion complex
(Figure 4 b) produced a pattern in which the crystalline S(-)
bvc has disappeared; in fact, the pattern in Figure 4b is similar
to the diffractogram related to HP- -CD, suggesting
conformational changes for S(-) bvc in the inclusion complex.
In the range 2 =5-60, the diffractogram for the complex has
a lower intensity than that for HP- -CD (see Figure 4a and
b), related to the reduced quantity of HP- -CD. The reduction
in the intensity was not 50%, compared to HP- -CD,
probably due to the contribution of the structural arrangement
of the S(-) bvc inside HP- -CD.
Varying the concentration of HP- -CD had no effect
on the cell viability. On the other hand, S(-) bvc reduced cell
viability in a dose-dependent manner, down to 57% (0.6 mM
S(-) bvc), while S(-) bvc: HP- -CD induced a maximum
inhibition (0.6 mM) comparable to that of HP- -CD, i.e.
affecting cell viability very little up to 2 hours after treatment
(p<0.001), compared to S(-) bvc (Figure 5). One of the
essential points about this in vitro toxicity model is that, since
the cytotoxic effects of S(-) bvc are dose-dependent, the
cellular protective effects observed on treatment with the
S(-)bvc:HP- -CD complex could be explained by the
sustained release of S(-) bvc from the HP- -CD cavity, as
demonstrated by in vitro drug-release assays (Araujo, et al. 2004).
The physicochemical characterization and in vitro
toxicity evaluation of an inclusion complex of S(-) bvc and
HP- -CD have been described. The complexation with HP-
-CD  generated a less toxic S(-) bvc formulation. Therefore,
we believe that this inclusion complex  may be a potential
therapeutic formulation for the treatment of pain. In vivo
biological tests have been carried out with this formulation
and will be published in due course.
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RESUMO
Caracterização morfológica e estudo de citotoxicidade do
complexo de inclusão entre S(-) bupivacaína e 2-
hidroxipropil- -ciclodextrina
Anestésicos locais são substâncias químicas que possuem
Figure 5. Cytotoxic effects of S(-) bvc, S(-) bvc:HP- -CD, HP- -CD at 0.2, 0.4
and 0.6 mM on Balb/c 3T3 cells incubated for 2 h at 37oC and 5% CO2 as
evaluated by MTT reduction test. Data expressed as % cell viability (Mean ±
SD, n=8 experiments). *** p<0.001 (one-way ANOVA with Tukey-Kramer post
hoc test).
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atividade farmacológica capaz de diminuir a dor devido
a ligação destes em canais de sódio voltagem dependentes
em membranas excitáveis, bloqueando a entrada de íons
sódio e a propagação do impulso nervoso. A S(-)
bupivacaína (S(-) bvc) é um anestésico local do tipo
aminoamida muito utilizado clinicamente. Neste estudo
foi realizada a caracterização morfológica e ensaios de
citotoxicidade do complexo de inclusão entre S(-) bvc e
2-Hidroxipropil- -ciclodextrina (HP- -CD). Análises de
calorimetria diferencial de varredura, microscopia
eletrônica de varredura e Raio-X mostraram mudanças
na morfologia do complexo de inclusão. Estudos iniciais
de citotoxicidade mostraram que o complexo de inclusão
diminui o efeito tóxico (p<0,001) da S(-) bvc. Estes
resultados sugerem que o complexo de inclusão entre
S(-)bvc e HP- -CD representam uma alternativa
promissora para o uso no tratamento da dor.
Palavras-chave:  S(-) bupivacaína; ciclodextrina; complexo
de inclusão.
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